After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.
The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by ...
FITBOOK magazine on MSN
Study Compares Effects of ‘Weight Loss Injections’ – This Compound Prevails
Not only celebrities are increasingly turning to the so-called "weight loss injection" to shed pounds. Now, two studies ...
Under the 'radical overhaul' of how obesity is diagnosed and treated, doctors would include other measures such as ...
I began by studying neuropeptides, but then my attention was caught by one specific hormone, expressed mainly in β-cells but ...
Key Takeaways A new ICD-10 diagnosis code, E11.A, now formally recognizes type 2 diabetes in remissionRemission requires an ...
Risk factors for CMV infection among adults with RMDs included diabetes, prior malignancy, IV cyclophosphamide, and initial prednisolone >0.91 mg/kg/day.
Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock surged 20% Wednesday after EMJ Capital Eric Jackson declared the ...
Paclitaxel-coated vs. uncoated devices did not reduce amputations in patients with chronic limb-threatening ischemia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback